PURPOSE: To identify and characterize the role of cytosolic phospholipase A(2) (cPLA(2)) in retinal angiogenesis using relevant cell-based assays and a rodent model of retinopathy of prematurity. METHODS: The phosphorylation states of cPLA(2) and p38 MAP kinase and the expression of COX-2 were assessed by Western blot analysis in rat Müller cells. The activities of PLA(2) enzymes in rat retinal lysates were assessed using a commercially available assay. Prostaglandin E(2) (PGE(2)) and VEGF levels in Müller cell-conditioned medium and in retinal tissue samples were measured by ELISA. Rat retinal microvascular endothelial cell proliferation was measured using a BrdU assay. Efficacy of the cPLA(2) inhibitor CAY10502 was tested using the rat model of oxygen-induced retinopathy (OIR) in which neovascularization (NV) was assessed by computer-assisted image analysis. RESULTS: In Müller cells, hypoxia increased the phosphorylation of cPLA(2) and p38 MAP kinase by 4-fold and 3-fold respectively. The cPLA(2) inhibitor CAY10502 decreased hypoxia-induced PGE(2) and VEGF levels in Müller cell-conditioned medium by 68.6% (P < 0.001) and 46.6% (P < 0.001), respectively. Retinal cPLA(2) activity peaked 1 day after oxygen exposure in OIR rats. CAY10502 (250 nM) decreased OIR-induced retinal PGE(2) and VEGF levels by 69% (P < 0.001) and 40.2% (P < 0.01), respectively. Intravitreal injection of 100 nM CAY10502 decreased retinal NV by 53.1% (P < 0.0001). CONCLUSIONS: cPLA(2) liberates arachidonic acid, the substrate for prostaglandin (PG) production by the cyclooxygenase enzymes. PGs can exert a proangiogenic influence by inducing VEGF production and by stimulating angiogenic behaviors in vascular endothelial cells. Inhibition of cPLA(2) inhibits the production of proangiogenic PGs. Thus, cPLA(2) inhibition has a significant influence on pathologic retinal angiogenesis.
PURPOSE: To identify and characterize the role of cytosolic phospholipase A(2) (cPLA(2)) in retinal angiogenesis using relevant cell-based assays and a rodent model of retinopathy of prematurity. METHODS: The phosphorylation states of cPLA(2) and p38 MAP kinase and the expression of COX-2 were assessed by Western blot analysis in rat Müller cells. The activities of PLA(2) enzymes in rat retinal lysates were assessed using a commercially available assay. Prostaglandin E(2) (PGE(2)) and VEGF levels in Müller cell-conditioned medium and in retinal tissue samples were measured by ELISA. Rat retinal microvascular endothelial cell proliferation was measured using a BrdU assay. Efficacy of the cPLA(2) inhibitor CAY10502 was tested using the rat model of oxygen-induced retinopathy (OIR) in which neovascularization (NV) was assessed by computer-assisted image analysis. RESULTS: In Müller cells, hypoxia increased the phosphorylation of cPLA(2) and p38 MAP kinase by 4-fold and 3-fold respectively. The cPLA(2) inhibitor CAY10502 decreased hypoxia-induced PGE(2) and VEGF levels in Müller cell-conditioned medium by 68.6% (P < 0.001) and 46.6% (P < 0.001), respectively. Retinal cPLA(2) activity peaked 1 day after oxygen exposure in OIR rats. CAY10502 (250 nM) decreased OIR-induced retinal PGE(2) and VEGF levels by 69% (P < 0.001) and 40.2% (P < 0.01), respectively. Intravitreal injection of 100 nM CAY10502 decreased retinal NV by 53.1% (P < 0.0001). CONCLUSIONS:cPLA(2) liberates arachidonic acid, the substrate for prostaglandin (PG) production by the cyclooxygenase enzymes. PGs can exert a proangiogenic influence by inducing VEGF production and by stimulating angiogenic behaviors in vascular endothelial cells. Inhibition of cPLA(2) inhibits the production of proangiogenic PGs. Thus, cPLA(2) inhibition has a significant influence on pathologic retinal angiogenesis.
Authors: Yusuke Mizukami; Won-Seok Jo; Eva-Maria Duerr; Manish Gala; Jingnan Li; Xiaobo Zhang; Michael A Zimmer; Othon Iliopoulos; Lawrence R Zukerberg; Yutaka Kohgo; Maureen P Lynch; Bo R Rueda; Daniel C Chung Journal: Nat Med Date: 2005-08-28 Impact factor: 53.440
Authors: Kathleen M Leahy; Richard L Ornberg; Yu Wang; Ben S Zweifel; Alane T Koki; Jaime L Masferrer Journal: Cancer Res Date: 2002-02-01 Impact factor: 12.701
Authors: Jennifer L Wilkinson-Berka; Nicole S Alousis; Darren J Kelly; Richard E Gilbert Journal: Invest Ophthalmol Vis Sci Date: 2003-03 Impact factor: 4.799
Authors: F Sennlaub; F Valamanesh; A Vazquez-Tello; A M El-Asrar; D Checchin; S Brault; F Gobeil; M H Beauchamp; B Mwaikambo; Y Courtois; K Geboes; D R Varma; P Lachapelle; H Ong; F Behar-Cohen; S Chemtob Journal: Circulation Date: 2003-06-23 Impact factor: 29.690
Authors: Andreas Stahl; Tim U Krohne; Przemyslaw Sapieha; Jing Chen; Ann Hellstrom; Emily Chew; Frank G Holz; Lois E H Smith Journal: Br J Ophthalmol Date: 2011-03-18 Impact factor: 4.638
Authors: C Motta; M Salmeri; C D Anfuso; A Amodeo; M Scalia; M A Toscano; G Giurdanella; M Alberghina; G Lupo Journal: Infect Immun Date: 2013-12-09 Impact factor: 3.441